Quest Diagnostics (DGX) Income from Non-Controlling Interests (2009 - 2026)
Quest Diagnostics (DGX) posted Income from Non-Controlling Interests of $14.0 million for Q2 2026, up 16.67% sequentially from $12.0 million in Q1 2026, and little changed YoY from $14.0 million in Q2 2025.
Quest Diagnostics (DGX) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Quest Diagnostics has reported Income from Non-Controlling Interests for 18 years, with the latest figure at $14.0 million in Q2 2026.
- Quarterly Income from Non-Controlling Interests changed 0.0% year-over-year to $14.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $51.0 million (down 5.56% YoY) and the FY2025 annual result came in at $54.0 million, up 8.0% from the prior year.
- Income from Non-Controlling Interests improved to $14.0 million in Q2 2026 per DGX's latest filing, from $12.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $20.0 million in Q3 2022 and troughed at $11.0 million in Q2 2024.
- A 5-year average of $14.1 million and a median of $14.0 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests tumbled 40.0% in 2023, then increased 27.27% in 2025.
- Over 5 years, Income from Non-Controlling Interests stood at $15.0 million in 2022, then declined by 13.33% to $13.0 million in 2023, then rose by 7.69% to $14.0 million in 2024, then slipped by 21.43% to $11.0 million in 2025, then climbed by 27.27% to $14.0 million in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $14.0 million, $12.0 million, and $11.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.86 Bn | 209.80 Bn | 8.34 Bn | 5.00 Mn |
| 2 | Danaher | 140.41 Bn | 136.07 Bn | 3.61 Bn | - |
| 3 | Idexx Laboratories | 46.33 Bn | 46.13 Bn | 779.09 Mn | - |
| 4 | Agilent Technologies | 39.71 Bn | 37.90 Bn | 990.00 Mn | - |
| 5 | Iqvia Holdings | 39.35 Bn | 37.27 Bn | 1.44 Bn | 2.00 Mn |
| 6 | Natera | 38.97 Bn | 37.87 Bn | 696.04 Mn | - |
| 7 | Illumina | 30.09 Bn | 28.92 Bn | 770.00 Mn | - |
| 8 | Mettler Toledo International | 28.70 Bn | 28.65 Bn | 650.22 Mn | - |
| 9 | Quest Diagnostics | 26.19 Bn | 25.56 Bn | 1.03 Bn | 14.00 Mn |
| 10 | Labcorp Holdings | 25.89 Bn | 24.91 Bn | 1.01 Bn | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.00 Mn |
| Mar 31, 2026 | 12.00 Mn |
| Dec 31, 2025 | 11.00 Mn |
| Sep 30, 2025 | 14.00 Mn |
| Jun 30, 2025 | 14.00 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 14.00 Mn |
| Sep 30, 2024 | 11.00 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Mar 31, 2024 | 14.00 Mn |
| Dec 31, 2023 | 13.00 Mn |
| Sep 30, 2023 | 12.00 Mn |
| Jun 30, 2023 | 14.00 Mn |
| Mar 31, 2023 | 15.00 Mn |
| Dec 31, 2022 | 15.00 Mn |
| Sep 30, 2022 | 20.00 Mn |
| Jun 30, 2022 | 16.00 Mn |
| Mar 31, 2022 | 18.00 Mn |
| Dec 31, 2021 | 23.00 Mn |
| Sep 30, 2021 | 22.00 Mn |